Description

BSE surveillance clarifications from Lippi Systems Limited, Aegis Logistics Ltd., and Bacil Pharma Ltd. regarding unusual price or volume movements in their equity shares, with all companies confirming no undisclosed material information.

Summary

BSE’s Online Surveillance team received clarification letters from three listed companies — Lippi Systems Limited (BSE: 526604), Aegis Logistics Ltd. (BSE: 500003), and Bacil Pharma Ltd. (BSE: 524516) — in response to queries regarding unusual price or volume movements in their respective equity shares. Each company has confirmed full compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and stated that no undisclosed material or price-sensitive information exists that could explain the observed market movements.

Key Points

  • Lippi Systems Limited responded to BSE query ref. L/SURV/ONL/PV/SJ/2025-2026/3396 (dated 24 Feb 2026) on price movement in its shares; attributes movement to market conditions, not any undisclosed event.
  • Aegis Logistics Ltd. responded to BSE query ref. L/SURV/ONL/PV/SG/2025-2026/936 (dated 25 Feb 2026) on volume movement; attributes increased volumes to investor interest driven by company performance and market forces.
  • Bacil Pharma Ltd. responded to BSE query ref. L/SURV/ONL/PV/SJ/2025-2026/3393 (dated 24 Feb 2026) on price movement; confirms no unpublished price-sensitive information or pending material developments.
  • All three companies affirm adherence to Regulation 30 of SEBI (LODR) Regulations, 2015 and commit to timely disclosure of future material events.
  • No management involvement in the price/volume movement is acknowledged by any of the companies.

Regulatory Changes

No regulatory changes are introduced by this circular. It is a disclosure document consolidating company responses to BSE surveillance queries under the existing framework of SEBI (LODR) Regulations, 2015.

Compliance Requirements

  • Companies queried by BSE Surveillance must respond promptly to price/volume movement inquiries.
  • Listed entities must continuously comply with Regulation 30 of SEBI (LODR) Regulations, 2015, ensuring timely disclosure of all material events and information.
  • Companies must confirm the absence of any undisclosed price-sensitive information when queried by the exchange.

Important Dates

  • 24 February 2026: BSE surveillance queries issued to Lippi Systems Limited and Bacil Pharma Ltd.; Bacil Pharma response dated same day.
  • 25 February 2026: BSE surveillance query issued to Aegis Logistics Ltd.; responses from Lippi Systems and Aegis Logistics dated same day; circular published.

Impact Assessment

The impact of this circular is minimal. It represents a routine surveillance mechanism employed by BSE to ensure market integrity and transparency. The responses from all three companies indicate no material undisclosed developments and no regulatory action is anticipated. Investors in Lippi Systems (526604), Aegis Logistics (500003), and Bacil Pharma (524516) should note that the respective managements have confirmed market-driven explanations for observed price/volume anomalies. No trading restrictions or compliance actions are indicated.

Impact Justification

Routine BSE surveillance clarifications with no material disclosures; all companies affirm compliance with SEBI LODR Regulation 30 and deny possession of undisclosed price-sensitive information, indicating normal market-driven movements.